<DOC>
	<DOCNO>NCT02099292</DOCNO>
	<brief_summary>The investigator prospectively evaluate combination Rituximab Dexa-BEAM ( dexamethasone , carmustine , etoposide , cytarabine , melphalan ) follow high dose therapy patient relapsed/refractory aggressive indolent lymphoma .</brief_summary>
	<brief_title>Rituximab DexaBEAM Salvage Therapy Relapsed Lymphoma</brief_title>
	<detailed_description>This study prospective , open label , single arm multicenter phase II study . It approve ethic committee participate center , regulatory issue principle GCP follow . The study initiated 2002 , recruitment close 2006 . Final data analysis perform 3/2013 . The trial register clinical trial database CIMT consortium The overall treatment plan brief , eligible patient treat two cycle R-DexaBEAM 3-4 week interval , stem cell mobilization schedule second cycle . Mobilization first cycle allow patient receive extensive prior therapy evidence BM-involvement found . HDT schedule within 4-8 week last R-DexaBEAM cycle patient achieve least PR . Protocols : The applied chemotherapy protocol follow : The salvage/mobilization-regimen consist R-DexaBEAM : Rituximab 375mg/m² d1 , dexamethasone 24 mg t.i.d p.o. , 1-10 ; BCNU 60mg/m² i.v. , 2 ; etoposide 75mg/m² i.v. , 4-7 ; cytarabin 200mg/m² b.i.d i.v. , 4-7 2 dos ; melphalan 20mg/m² i.v. , d3 . For high dose radio/chemotherapy , two different condition regimen define protocol : chemo-radiotherapy R-TBI/Cy consist Rituximab 375mg/m² i.v . -7 , -2 , fractionate total body irradiation 12 Gy , -6 -4 ; cyclophosphamide 60 mg/kgbw i.v. , day -3 -2 . The chemotherapy protocol use condition R-BEAM : Rituximab 375mg/m² i.v . -8 , -2 , BCNU 300mg/m² i.v. , -7 ; cytarabin 400mg/m² b.i.d . i.v. , -6 -3 ; etoposide 200mg/m² i.v . b.i.d. , -6 -3 ; melphalan 140mg/m² i.v. , -2 . Stem cell mobilization : Following mobilization chemotherapy , stem cell collect G-CSF stimulation ( 5-10µg/kg bw/d , start day 11 R-DexaBEAM ) use standard apheresis procedure , stem cell process cryopreserved accord local standard . A minimum number 2x106/kgbw CD34 positive cell require conduct high dose therapy . Autologous stem cell transfusion : For stem cell rescue HDT , least 2x106/kg CD34 positive cell apply . Stem cell thaw bedside infused via central venous catheter . Concomitant treatment conduct accord local standard , e.g . antiemetic prophylaxis , hydration parenteral nutrition . At time trial initiation , prophylactic antibiotic treatment recommend due local standard , e.g . ciprofloxacin . For PJP prophylaxis co-trimoxazole mandatory recovery CD4-cell count 200/µl reach day 100 post stem cell re-transfusion . In case symptomatic CMV-reactivation , treatment ganciclovir recommend . In addition , maintenance immunoglobulin level concentration &gt; 5g/l recommend . G-CSF support optional salvage high dose therapy ( 5µg/kgbw ) . Diagnostic evaluation : Throughout entire treatment , routine laboratory investigation perform . In addition , CMV-reactivation screen mandatory CMV positive patient . stag procedure include CT-scans schedule baseline , prior HDT 2 , 6 , 9 , 12 , 18 , 24 , 36 month HDT , thereafter clinically indicate . Responses assess use criterion Cheson et al . BM evaluate baseline , re-evaluation need confirm complete remission . Statistical analysis The primary efficacy endpoint study progression-free survival ( PFS ) , calculate intent-to-treat population . Event-free survival define time date trial inclusion time either disease progression death ( irrespective cause ) late follow-up without progression . Secondary efficacy endpoint overall response rate day 60 post stem cell re-transfusion , overall survival ( time inclusion death , irrespective cause ) , safety side effect , toxicity high dose therapy accord Bearman score , number CMV-reactivations . Further endpoint , report separately , percentage patient negative minimal residual disease ( MRD ) either ( 14 ; 18 ) - FL ( 11 ; 14 ) - MCL PCR , time immune reconstitution achievement CD4 count 200/µl . Results time-to-event endpoint analyse accord Kaplan-Meier estimator , comparison perform log-rank test . P &lt; 0.05 consider statistically significant . GraphPad Prism version 5.0 Windows , ( GraphPad Software , CA , USA ) use calculation . Statistical advice give Institute Epidemiology Biometrical Statistics University Mainz .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>age 18 65 year Patients aggressive Bcelllymphoma : diffuse large Bcell lymphoma ( DLBCL ) , mantle cell lymphoma ( MCL ) grade IIIB follicular lymphoma ( FL ) relapse complete remission ( CR ) failure achieve CR treatment . Patients indolent lymphoma : FL grade IIIIA , marginal zone lymphoma ( MZL ) immunocytoma ( IC ) relapse failure achieve least partial remission ( PR ) treatment . CD20 positive previous therapy : least 3 cycle anthracycline contain regimen . ECOG ( Eastern Cooperative Oncology Group ) 02 measurable disease adequate bone marrow function ( absolute neutrophil count [ ANC ] &gt; 1500/µl ; platelet count &gt; 100,000/µl ) , unless clear evidence bone marrow involvement glomerular filtration rate &gt; 60ml/min ASAT ( aspartate transaminase ) /ALAT ( alanine aminotransferase ) &lt; 2.5fold upper limit normal ( ULN ) unless associate liver infiltration free cancer least 5 year , exception basal cell carcinoma carcinoma situ uterine cervix . give informed consent ( central nervous system ) CNSlymphoma HIV Hepatitis B C pregnancy breastfeed woman high dose therapy allogeneic transplantation glomerular filtration rate &lt; 60ml/min ASAT/ALAT &gt; 2.5fold upper limit normal ( ULN ) unless associate liver infiltration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>lymphoma</keyword>
	<keyword>high dose therapy</keyword>
	<keyword>DexaBEAM</keyword>
	<keyword>Rituximab</keyword>
	<keyword>role alternative salvage treatment - dexaBEAM</keyword>
</DOC>